» Articles » PMID: 853125

Erythroid Colony Formation by Polycythemia Vera Bone Marrow in Vitro. Dependence on Erythropoietin

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1977 May 1
PMID 853125
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

In the plasma clot culture system both normal and polycythemia vera (PV) bone marrow cells respond to erythropoietin (Ep), giving rise to large numbers of colonies of erythroid cells. In PV, but not in normal individuals, the marrow produced endogenous erythroid colonies (EED) in the absence of exogenous Ep. The number of EEC formed varied from patient to patient comprising anywhere from 6 to 29% of the total number of colonies formed in the presence of Ep. Exposure, before use in culture, of fetal calf serum and citrated bovine plasma to the gammaglobulin fraction of rabbit anti-Ep serum followed by treatment with goat anti-rabbit gamma-globulin re sulted in a significant decrease in EEC formation. Addition of anti-Ep directly to the culture medium produced similar results. In addition, the production of EEC in response to added Ep was inhibited in the presence of anti-Ep. Addition of very small doses of highly purified Ep to anti-Ep-treated cultures resulted in the reappearance of a significantnumber of EEC formation in PV may be due to a population of erythroid-committed precursors that are abnormally sensitive to small concentrations of Ep which may be present in fetal calf serum and citrated plasma. Although the mechanism of formation of these cells is not known, it appears that the final steps in the formation of red cells derived from this clone of precursors is subject to the usual Ep control.

Citing Articles

Quantification of IGF-1 Receptor May Be Useful in Diagnosing Polycythemia Vera-Suggestion to Be Added to Be One of the Minor Criterion.

Wang J, Shi G, Baptiste S, Yarotska M, Sindhu H, Wong C PLoS One. 2016; 11(11):e0165299.

PMID: 27812134 PMC: 5094699. DOI: 10.1371/journal.pone.0165299.


Targeting JAK2 in the therapy of myeloproliferative neoplasms.

Reddy M, Deshpande A, Sattler M Expert Opin Ther Targets. 2012; 16(3):313-24.

PMID: 22339244 PMC: 4051134. DOI: 10.1517/14728222.2012.662956.


The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.

Wadleigh M, Gilliland D Curr Hematol Malig Rep. 2010; 1(2):75-80.

PMID: 20425335 DOI: 10.1007/s11899-006-0026-3.


Polycythemia vera.

Landolfi R, Nicolazzi M, Porfidia A, Di Gennaro L Intern Emerg Med. 2010; 5(5):375-84.

PMID: 20237866 DOI: 10.1007/s11739-010-0369-6.


Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.

Quintas-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle P Blood. 2010; 115(15):3109-17.

PMID: 20130243 PMC: 3953826. DOI: 10.1182/blood-2009-04-214957.


References
1.
SCHOOLEY J, Garcia J . SOME PROPERTIES OF SERUM OBTAINED FROM RABBITS IMMUNIZED WITH HUMAN URINARY ERYTHROPOIETIN. Blood. 1965; 25:204-17. View

2.
WEINTRAUB A, Gordon A, CAMISCOLI J . USE OF THE HYPOXIA-INDUCED POLYCYTHEMIC MOUSE IN THE ASSAY AND STANDARDIZATION OF ERYTHROPOIETIN. J Lab Clin Med. 1963; 62:743-52. View

3.
Gordon A . Erythropoietin. Vitam Horm. 1973; 31:105-74. DOI: 10.1016/s0083-6729(08)60997-8. View

4.
Adamson J . The erythropoietin-hematocrit relationship in normal and polycythemic man: implications of marrow regulation. Blood. 1968; 32(4):597-609. View

5.
SCHOOLEY J, Garcia J, Cantor L, Havens V . A summary of some studies on erythropoiesis using anti-erythropoietin immune serum. Ann N Y Acad Sci. 1968; 149(1):266-80. DOI: 10.1111/j.1749-6632.1968.tb15161.x. View